Pacific Biosciences Of California (PACB) Asset Writedowns and Impairment (2022 - 2025)

Pacific Biosciences Of California's Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $5.2 million for Q4 2025.

• On a quarterly basis, Asset Writedowns and Impairment fell 85.58% year-over-year to $5.2 million in Q4 2025; TTM through Mar 2026 was $5.2 million, a 96.19% decrease from a year earlier, with the FY2025 full-year figure at $15.0 million, down 62.5% from the prior year.
• Asset Writedowns and Impairment declined to $5.2 million in Q4 2025 per PACB's latest filing, from $7.7 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $93.2 million in Q2 2024 and bottomed at -$4.7 million in Q4 2023.
• The 4-year median for Asset Writedowns and Impairment is $878000.0 (2022), against an average of $11.0 million.
• Across the five-year window, Asset Writedowns and Impairment sank 99.91% in 2024 and surged 255200.0% in 2025, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at -$2.7 million in 2022, then tumbled by 75.89% to -$4.7 million in 2023, then surged by 873.5% to $36.3 million in 2024, then tumbled by 85.58% to $5.2 million in 2025.
• Per Business Quant, the three latest PACB Asset Writedowns and Impairment figures stand at $5.2 million (Q4 2025), $7.7 million (Q1 2025), and $36.3 million (Q4 2024).